跳到正文

全部动态

今日 54 条
9月11日周五
  1. Servier5

    🚀 欢迎参加下一届施维雅 Partnering Day,11月23日,地点在我们的巴黎-萨克雷研发研究所! 与制药和生物技术领袖、企业家、投资者和研究人员交流,探索医疗健康领域的合作机会与创新。🔬🤝 活动包括研发洞察、领导力讨论、社交、1对1会议和实地参观,并特别聚焦 Servier Ventures。 📅 11月23日 | 10月1日前注册:https://f.mtr.cool/chv9mhmd7m #WeAreServier #Innovation #Partnerships @BioLabsFr

  2. Ashish K. Jha15

    @AnthropicAI 的 @nc_frey 这些人是好人 他们有护栏。他们会关注谁在用他们的工具做潜在的恶意事情 而且他们会采取行动 你没看到其他人有类似报告,这件事本身不应该让你感到安心

    引用Nathan C. Frey@nc_frey

    Today we’re sharing some case studies of threat actors attempting to use Claude for malicious activity, including developing biological weapons. This is the first time any private company, to our knowledge, has publicly shared evidence of potential misuse of their platform for biological weapons development. Our goals are to enable the professional, legitimate life sciences research done with Claude, realize the incredible beneficial impacts for human health and medicine, and ensure that every AI platform is able to recognize and prevent misuse. Sophisticated, state-affiliated actors don’t tell Claude “I’m from adversarial nation X, build me a bioweapon.” They deliberately mask their origin and go to extreme lengths to obfuscate their intent and make their requests seem benign. When we detect and disrupt them, they route traffic to models with more permissive safeguards. Some attempts are easier to detect, like attempts to engineer viruses to infect humans or spread more efficiently. Our Life Sciences Verification Program is designed to enable beneficial research and prevent harmful use cases. We know our bio safeguards are not perfect, and can be a source of major frustration for professional researchers, but we are iterating constantly to make them better at preventing misuse and to improve the user experience for legitimate research. https://www.anthropic.com/threat-intelligence-report-september-2026

  3. NICE62

    NICE 推荐一款新的多发性骨髓瘤治疗方案,适用于新诊断患者,超过 1,760 人可能从中受益。NICE 表示,证据显示该方案相比标准治疗可帮助患者延长生存时间,并更长时间控制疾病。相关指南文件已在 NICE 官网的指南制定页面公布。

    推荐理由:NICE 推荐多发性骨髓瘤新治疗方案,读者可了解该推荐覆盖的患者规模及其相对标准治疗的证据依据。

9月10日周四
  1. NICE22

    我们欢迎国家 AI 委员会报告的发布。 关于临床有效性和价值的独立证据,对于支持在健康与护理领域采用 AI 技术做出知情决策至关重要。NICE 将在这方面发挥作用,与 @DHSCgovuk 一道。

    引用MHRAgovuk@MHRAgovuk

    📢 New recommendations by the NHS doctor-led National AI Commission, informed by 12,000+ people's views, on how the UK can safely speed up access to AI to support clinicians and benefit patients balancing innovation with patient safety. Read more 🔗https://brnw.ch/21x5zQN